Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018)
Eton Pharmaceuticals' (ETON) quarterly Preferred Stock Liabilities came in at $21.2 million in Q3 2018, up 11.35% quarter-over-quarter from $19.0 million in Q4 2017.
Analysis
Eton Pharmaceuticals (ETON) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Eton Pharmaceuticals has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $21.2 million for Q3 2018.
- In Q3 2018, Preferred Stock Liabilities changed N/A year-over-year to $21.2 million; the TTM figure through Sep 2018 stood at $21.2 million (changed N/A YoY), while the FY2017 annual figure was $19.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $21.2 million for Q3 2018 at Eton Pharmaceuticals, up from $19.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $21.2 million in Q3 2018 to a low of $19.0 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Eton Pharmaceuticals | 1.63 Bn | 1.60 Bn | 25.41 Mn | - |